What is Zacks Research’s Estimate for VRTX Q1 Earnings?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities research analysts at Zacks Research lowered their Q1 2025 earnings estimates for shares of Vertex Pharmaceuticals in a research report issued to clients and investors on Thursday, January 23rd. Zacks Research analyst R. Department now anticipates that the pharmaceutical company will post earnings of $3.51 per share for the quarter, down from their prior forecast of $3.82. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($1.90) per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q2 2025 earnings at $3.76 EPS.

A number of other research firms also recently issued reports on VRTX. Canaccord Genuity Group boosted their price target on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a research note on Wednesday, November 6th. Cantor Fitzgerald restated an “overweight” rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday. HC Wainwright decreased their price target on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating on the stock in a research report on Friday, December 20th. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Friday, December 20th. Finally, UBS Group raised their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $494.84.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $439.62 on Monday. The firm has a market capitalization of $113.21 billion, a PE ratio of -220.91, a P/E/G ratio of 2.20 and a beta of 0.40. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $435.36 and a 200-day moving average price of $464.51. Vertex Pharmaceuticals has a 52 week low of $377.85 and a 52 week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the company earned $3.67 EPS.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. State Street Corp increased its position in shares of Vertex Pharmaceuticals by 0.8% during the 3rd quarter. State Street Corp now owns 11,816,249 shares of the pharmaceutical company’s stock valued at $5,495,501,000 after purchasing an additional 90,173 shares during the last quarter. Jennison Associates LLC boosted its stake in Vertex Pharmaceuticals by 18.1% during the third quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock worth $2,581,373,000 after buying an additional 851,054 shares during the period. Wellington Management Group LLP increased its position in Vertex Pharmaceuticals by 17.2% during the third quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company’s stock valued at $2,231,858,000 after acquiring an additional 704,421 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Vertex Pharmaceuticals by 5.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,905,705 shares of the pharmaceutical company’s stock valued at $1,351,385,000 after acquiring an additional 159,693 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in shares of Vertex Pharmaceuticals by 4.1% in the 3rd quarter. Janus Henderson Group PLC now owns 2,516,831 shares of the pharmaceutical company’s stock worth $1,170,506,000 after acquiring an additional 100,114 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.